FibroBiologics Takes the Stage at the BIO International Convention
FibroBiologics, Inc. (Nasdaq: FBLG), a pioneering clinical-stage biotechnology company, is set to share significant advancements in the treatment of chronic diseases. Known for its impressive portfolio of over 275 issued and pending patents, FibroBiologics focuses on harnessing fibroblasts and fibroblast-derived materials to create therapeutics that could potentially transform patient outcomes in various serious health conditions.
Presentation Highlights and Vision
At the esteemed BIO International Convention scheduled for June 16-19, FibroBiologics' Founder and CEO, Pete O’Heeron, will present the company’s latest updates. The conference represents a perfect opportunity for FibroBiologics to delve into the company’s progress and strategic direction, particularly in therapies targeted at chronic diseases like multiple sclerosis, psoriasis, and wound healing.
"This convention provides a platform to showcase how FibroBiologics is potentially reshaping the treatment landscape for chronic diseases," stated O’Heeron. He emphasized the importance of their upcoming Phase 1/2 clinical trial focusing on diabetic foot ulcers, which aims to address the underlying causes through innovative fibroblast therapies rather than merely treating symptoms. This could signify a paradigm shift in chronic disease management.
Event Details
O’Heeron’s presentation is scheduled for:
Date: Tuesday, June 17
Time: 10:45 a.m. ET
Location: Boston Convention & Exhibition Center, Room 154
Commitment to Innovation
FibroBiologics is not only committed to advancing treatment methodologies but also to enhancing the efficacy of existing therapies. Their research utilizes fibroblast technology, aiming to provide biological solutions for complex conditions. This approach underscores the company's ethos of targeting fundamental biological issues that contribute to chronic illnesses, offering a glimpse into the future of personalized medicine.
About FibroBiologics
Based in Houston, FibroBiologics has garnered attention in the biotechnology space with its unique approach towards leveraging fibroblast cells. The company is developing an extensive range of therapies that may address significant health issues like wound healing, disc degeneration, and even facets of cancer treatment. Their commitment to research and development is indicative of the potential breakthroughs that lie ahead.
General and Investor Inquiries
For those seeking more information about FibroBiologics, inquiries can be directed to:
Email: info@fibrobiologics.com
Media Contact: Liz Phillips,
Russo Partners,(347) 956-7697
Email: Elizabeth.phillips@russopartnersllc.com
Investor Relations:
Nic Johnson,
Russo Partners,
(212) 845-4242,
Email: fibrobiologicsIR@russopr.com
Frequently Asked Questions
What innovations are expected from FibroBiologics?
FibroBiologics is anticipated to showcase new therapeutic approaches utilizing fibroblast technology to target chronic diseases directly.
What is the significance of the BIO International Convention for FibroBiologics?
The convention serves as a platform to highlight FibroBiologics' progress, engage with industry leaders, and share vital clinical updates.
Who will present on behalf of FibroBiologics?
Pete O’Heeron, the Founder and CEO of FibroBiologics, will present at the convention.
What chronic diseases is FibroBiologics focusing on?
The company is focusing on multiple conditions, including diabetic foot ulcers, multiple sclerosis, psoriasis, and other chronic diseases.
How can interested parties contact FibroBiologics?
Stakeholders can reach out via email at info@fibrobiologics.com for general inquiries or connect with investor relations through fibrobiologicsIR@russopr.com.
